| 达沙替尼应用于伊马替尼耐药的慢性粒细胞白血病的研究进展 |
| |
| 引用本文： | 燕玮,杨威. 达沙替尼应用于伊马替尼耐药的慢性粒细胞白血病的研究进展[J]. 辽宁药物与临床, 2012, 0(2): 108-110 |
| |
| 作者姓名： | 燕玮 杨威 |
| |
| 作者单位： | 中国医科大学附属盛京医院血液内科,沈阳110004 |
| |
| 摘 要： | 伊马替尼是一种酪氨酸激酶抑制剂（TKI）,是第一代用于治疗Ph染色体阳性的CML的分子靶向药物,然而其逐渐出现的耐药情况是治疗的一大难题。第二代靶向治疗药物如达沙替尼等具有更大的抗耐药潜力。本文对此进行综述。
|
| 关 键 词： | 达沙替尼 耐药 慢性粒细胞白血病（CML） |
Research progress on imatinib-resistant chronic myeloid leukemia therapy using dasatinib |
| |
| YAN Wei,YANG Wei. Research progress on imatinib-resistant chronic myeloid leukemia therapy using dasatinib[J]. Liaoning Pharmacy and Clinical Remedies, 2012, 0(2): 108-110 |
| |
| Authors: | YAN Wei YANG Wei |
| |
| Affiliation: | (Department of Hematology,Shengjing Hospital of China Medical University,Shenyang 110004,China) |
| |
| Abstract: | Imatinib is a kind of tyrosine kinase inhibitors and is the first generation targeted molecular medicine used in the treatment of Ph chromosome positive CML.However,gradually appearing of its drug resistance is a big problem in the treatment.The second generation targeted molecular medicine such as dasatinib is more potential for anti-drug resistance.This review is based on these. |
| |
| Keywords: | Dasatinib Drug resistance Chronic myeloid leukemia（CML） |
| 本文献已被 维普 等数据库收录！ |
